New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: glycerol hydrochloric acid as 10% solution for ph adjustment metacresol sodium hydroxide as 10% solution for ph adjustment water for injection - humulin is indicated for the treatment of insulin-requiring diabetes mellitus.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - insulin,isophane (nph) -

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 200 iu/ml - injection, solution - excipient ingredients: glycerol; zinc oxide; trometamol; water for injections; hydrochloric acid; sodium hydroxide; metacresol - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; water for injections; metacresol; protamine sulfate; dibasic sodium phosphate heptahydrate; phenol; glycerol; zinc oxide; hydrochloric acid - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; glycerol; phenol; water for injections; dibasic sodium phosphate heptahydrate; metacresol; zinc oxide; sodium hydroxide; protamine sulfate - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; phenol; hydrochloric acid; glycerol; metacresol; sodium hydroxide; zinc oxide; water for injections; dibasic sodium phosphate heptahydrate - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin -